Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 6/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | CD69 | Q07108 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.45 |
| ▸ | CDKL2 | Q92772 | 1/20 | 0.45 |
| ▸ | RIOK1 | Q9BRS2 | 1/20 | 0.45 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.45 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.31 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16793852 | 0.89 | BTK (0.47) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL20027005 | 0.81 | BTK (0.41) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL18183911 | 0.77 | BTK (0.48) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL25590604 | 0.77 | BTK (0.53) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL16793564 | 0.77 | BTK (0.53) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL25176701 | 0.74 | ROCK1 (0.40) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL25584965 | 0.70 | BTK (0.59) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL20461055 | 0.70 | BTK (0.61) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL29676771 | 0.69 | BTK (0.59) | BTKJAK2CYP3A4HRH2CDK7 | |
| SCHEMBL16793760 | 0.69 | BTK (0.59) | BTKJAK2CYP3A4HRH2CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885JAK2 20/4885CYP3A4 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.